IRIS Pharma
A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY
  • HOME
  • ABOUT US

    • Overview »

      • Introduction
      • Mission and values
      • Equipment
      • History
    • Partnerships
  • SERVICES

    • Overview
    • Consulting & communication »

      • Strategic and global drug development consulting
      • Communication
    • Preclinical studies »

      • Overview
      • Pilot and proof of concept studies
      • Regulatory studies (GLP) »

        • Ocular tolerance and safety assessment
        • Ocular pharmacokinetics
      • Efficacy studies »

        • Overview
        • Ocular Angiogenesis
        • Ocular Neurodegeneration
        • Ocular Hypertension
        • Ocular Allergy
        • Ocular Inflammation
        • Uveitis
        • Conjunctivitis
        • Ocular Pain
        • Ocular infection
        • Corneal wound healing
        • Diabetic retinopathy
        • Dry eye
        • Ocular implantation
      • Preclinical formulation
      • Novel in vivo model
      • Ocular histopathology
    • Clinical trials »

      • Overview
      • Therapeutic expertise
      • Countries
      • Clinical trial services »

        • Phase 1-4 and marketing studies
        • CRA
        • Project management
        • Medical writing
        • Regulatory affairs
        • Statistics / Data management
      • Quality assurance
      • Patient and Investigator recruitment
    • Bioanalytical testing services
    • Global drug development
  • FOCUS IN OPHTHALMOLOGY

    • Eye structures
    • Ocular pathologies
    • Drug development process
    • Ocular drug delivery methods
    • Photo gallery
  • NEWS AND EVENTS

    • News
    • Upcoming events
  • RESOURCES

    • Publications
    • Patents
    • Library
    • Links
  • CONTACT

Overview

Consulting & communication

» Strategic and global drug development consulting

» Communication

Preclinical studies

» Overview

» Pilot and proof of concept studies

» Regulatory studies (GLP)

- Ocular tolerance and safety assessment

- Ocular pharmacokinetics

» Efficacy studies

- Overview

- Ocular Angiogenesis

- Ocular Neurodegeneration

- Ocular Hypertension

- Ocular Allergy

- Ocular Inflammation

- Uveitis

- Conjunctivitis

- Ocular Pain

- Ocular infection

- Corneal wound healing

- Diabetic retinopathy

- Dry eye

- Ocular implantation

» Preclinical formulation

» Novel in vivo model

» Ocular histopathology

Clinical trials

» Overview

» Therapeutic expertise

» Countries

» Clinical trial services

- Phase 1-4 and marketing studies

- CRA

- Project management

- Medical writing

- Regulatory affairs

- Statistics / Data management

» Quality assurance

» Patient and Investigator recruitment

Bioanalytical testing services

Global drug development

Bookmark
Print
Send to a friend
Home » Services » Preclinical studies » Efficacy studies » Ocular Pain
Ocular pain

Models:

  • Capsaicin-induced ocular pain
  • Formalin-induced eye discomfort

Administration: topical ocular administration

 

Animal: albino rabbit

 

Evaluation:

  • mesurement of the palpebral opening
  • observing the conjunctival hyperemia
  • counting the number of blinkings

Reference substances: Capsazepine

 

For information on animal model of Ocular Pain, please contact Iris Pharma at info@iris-pharma.com or call +33 4 93 59 49 59.

IRIS Pharma
Services
Overview
Consulting & communication
Preclinical studies
Clinical trials
Bioanalytical testing services
Global drug development
IRIS Pharma
Preclinical studies
Overview
Pilot and proof of concept studies
Ocular tolerance and safety assessment
Ocular pharmacokinetics
Efficacy studies
Preclinical formulation
Novel in vivo model
Ocular histopathology
IRIS Pharma
Clinical trials
Overview
Therapeutic expertise
Countries
Clinical trial services
Quality assurance
Patient and Investigator recruitment
IRIS Pharma
Focus in ophthalmology
Eyes structure
Ocular pathologies
Drug development process
Ocular drug delivery methods
Photo gallery
IRIS Pharma
Sitemap
IRIS Pharma
Privacy policy
IRIS Pharma
Contact us
IRIS Pharma
Restricted area
© Iris Pharma 2013